Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
Stepan Company (SCL) reported third-quarter 2026 net sales of $692.2 million, up 17% year over year. Reported net income was $17.8 million, up 64%; adjusted net income was $21.7 million, up 98%; and adjusted EBITDA was $66.3 million, up 18%. Cash from operations was $29.3 million, while free cash flow was $8.2 million and was negatively impacted by higher working capital requirements. A $5.6 million pre-tax restructuring charge related to Project Catalyst included approximately 100 salaried position reductions, or 7% of global salaried headcount.
For the first nine months, Stepan reported a $0.7 million net loss versus $41.9 million of income a year earlier; it said the current-year loss was entirely due to a $76.1 million pre-tax restructuring charge. Adjusted net income was $59.1 million, up 40%, and adjusted EBITDA was $190.3 million, up 15%. In October, Stepan closed the sale of a parcel near its Millsdale site for $28.5 million; full cash proceeds will be used to pay down debt. The board declared a $0.405-per-share quarterly dividend, payable December 15, 2026, to holders of record December 1; the dividend increased by $0.010 per share, marking the 59th consecutive year of increases.
Stepan Co (SCL) is the issuer in a Schedule 13G reporting that Dimensional Fund Advisors had an amount beneficially owned of 1,192,015 common shares, or 5.2%, as of September 30, 2026. Dimensional reported sole voting power over 1,165,503 shares and sole dispositive power over 1,192,015 shares; shared voting and dispositive power were zero. Dimensional states that the shares are owned by the Funds it advises, sub-advises or manages, and disclaims beneficial ownership.
Stepan Company (SCL) entered into a credit agreement on September 25, 2026, providing $500.0 million of initial aggregate principal: a $350.0 million multicurrency revolving credit facility and a $150.0 million delayed draw term loan credit facility. Both mature on September 25, 2031. The facilities replace the prior $350.0 million revolving facility and $100.0 million delayed draw term loan facility. Stepan may draw as needed for working capital, permitted acquisitions, capital expenditures and general corporate purposes. The agreement also allows Stepan, subject to certain requirements, to request increased revolving capacity or incremental term loans totaling up to an additional $250.0 million.
Interest rates depend on Stepan’s net leverage ratio: a base rate plus 0.125% to 0.625%, or a term benchmark or Adjusted Daily Simple RFR plus 1.125% to 1.625%. Stepan must maintain interest coverage and net leverage ratios and comply with covenants that include limits on restricted payments, indebtedness and liens.
STEPAN CO (SCL) reported insider equity activity by officer Shawn G. Lisle (VP GC & Secretary). On 2026-08-26, Lisle exercised 1,154 restricted stock units (RSUs), receiving an equal number of common shares per the award terms. To cover tax liability on the RSU vesting, 339 common shares were withheld at $62.345 per share. Following the exercise, Lisle holds 2,308 RSUs, each representing a contingent right to receive one share of Stepan common stock.
Stepan Co senior vice president and chief financial officer Ruben Dario Velasquez reported the vesting and settlement of 1,358 Restricted Stock Units (RSUs) on August 10, 2026. Each RSU represented a contingent right to receive one share of common stock, and the RSUs were settled in common shares at a reference price of $64.675 per share. In connection with the vesting, 398 common shares were withheld to satisfy tax liabilities, with the remainder retained as directly owned common stock. After the derivative transaction, 2,716 RSUs remained outstanding, vesting ratably over three years beginning on the award date.
Stepan Company reported stronger Q2 2026 results, with net sales of $ 684,109 (in thousands) up from $ 594,689, gross profit of $ 99,982, operating income of $ 37,210 and net income of $ 22,911, or $ 1.00 per basic and diluted share.
For the first six months of 2026, net sales were $ 1,288,618 (in thousands) versus $ 1,187,944, but a business restructuring charge of $ 70,545 and higher unallocated corporate expenses drove an operating loss of $ ( 12,412 ) and a net loss of $ ( 18,495 ), compared with net income of $ 31,052 a year earlier.
Operating cash flow for the six months was $ 25,298 (in thousands), capital expenditures were $ 54,294, cash and cash equivalents were $ 113,705, and total debt including current maturities was $ 647,571 at June 30, 2026. The company accrued environmental and legal reserves of $ 19,619 within an estimated loss range up to $ 46,483.
Stepan Company VP, Controller & PAO Matthew John Eaken filed an initial statement of beneficial ownership reporting 9,319 shares of Stepan common stock held directly and 3,102 shares held indirectly through an ESOP II Trust. He also reports a portfolio of stock options and stock appreciation rights on Stepan common stock with exercise prices between $50.06 and $123.73, plus performance share and restricted stock unit awards, each representing contingent rights to receive Stepan common shares based on vesting schedules or performance goals.
Stepan Company reported strong second‑quarter 2026 results, with net sales of $684.1 million, up 15% year‑over‑year. Net income more than doubled, with diluted earnings per share of $1.00. Adjusted earnings per share were $1.18, more than double the prior‑year quarter, and consolidated adjusted EBITDA rose 45% to $74.4 million, driven mainly by Surfactants and Polymers volume growth and margin recovery.
For the first half of 2026, reported results reflected $70,545 thousand of Business Restructuring expense tied to Project Catalyst, leading to a reported net loss even as adjusted net income rose 20%. The Board approved a plan to reduce the global salaried workforce by around 100 roles, expecting approximately $4–6 million of primarily cash restructuring charges, largely in the second half of 2026, within the previously disclosed $75–80 million full‑year Project Catalyst range.
Director Jan Stern Reed resigned from the Board and its committees without a disagreement, and new committee chairs were appointed. Matthew J. Eaken was named Principal Accounting Officer. The Board declared a quarterly dividend of $0.395 per share, payable September 15, 2026. Management stated that, despite macro uncertainties, they believe the company will deliver full‑year adjusted EBITDA growth, positive free cash flow and continued balance‑sheet de‑leveraging in 2026.
Stepan Company VP and GM Surfactants-INT Robin Joseph Weitkamp reported routine compensation-related equity activity involving restricted stock units (RSUs) and common stock.
On May 11, 2026, 90 RSUs were settled into 90 shares of common stock per the award terms. To cover tax obligations on the RSU vesting, 50 shares of common stock were withheld at a value of $52.58 per share, leaving 40 shares of common stock held directly after the transactions. The filing also shows 96.9 shares of common stock held indirectly through the ESOP II Trust.
Stepan Company vice president, general counsel and secretary Shawn G. Lisle reported equity compensation awards and a correction to a prior filing. On March 2, 2026, he received 6,440 stock appreciation rights with a conversion price of $50.06, 2,247 performance shares, and 4,495 restricted stock units, each tied to one share of common stock. A separate February 27, 2026 entry shows a grant of 25.544 shares of common stock at $52.51 per share. The amendment updates the previously reported stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.